Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80779 |
Name | plasmablastic lymphoma |
Definition | A large B-cell lymphoma that is characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma large B-cell lymphoma plasmablastic lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03129828 | Phase Ib/II | Bortezomib + Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate | Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI >= 2 (ImbruVeRCHOP) | Active, not recruiting | DEU | 0 |
NCT04676360 | Phase II | belantamab mafodotin-blmf | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT04915248 | Phase II | Bortezomib + Daratumumab + Dexamethasone | Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (FIL_DALYA) | Recruiting | ITA | 0 |
NCT05270057 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (LONCA) | Recruiting | USA | 0 |